198 related articles for article (PubMed ID: 22760521)
1. Immuno-SPET/CT and immuno-PET/CT: a step ahead to translational imaging.
Pecking AP; Bellet D; Alberini JL
Clin Exp Metastasis; 2012 Oct; 29(7):847-52. PubMed ID: 22760521
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Immuno-PET Imaging and Radioimmunotherapy of 64Cu-/177Lu-Labeled Anti-EGFR Antibody in Esophageal Squamous Cell Carcinoma Model.
Song IH; Lee TS; Park YS; Lee JS; Lee BC; Moon BS; An GI; Lee HW; Kim KI; Lee YJ; Kang JH; Lim SM
J Nucl Med; 2016 Jul; 57(7):1105-11. PubMed ID: 26917708
[TBL] [Abstract][Full Text] [Related]
4. Current Perspectives on
Yoon JK; Park BN; Ryu EK; An YS; Lee SJ
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560337
[No Abstract] [Full Text] [Related]
5. Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis.
Padia SA; Alessio A; Kwan SW; Lewis DH; Vaidya S; Minoshima S
J Vasc Interv Radiol; 2013 Aug; 24(8):1147-53. PubMed ID: 23792126
[TBL] [Abstract][Full Text] [Related]
6. Beyond 18F-FDG: Characterization of PET/CT and PET/MR Scanners for a Comprehensive Set of Positron Emitters of Growing Application--18F, 11C, 89Zr, 124I, 68Ga, and 90Y.
Soderlund AT; Chaal J; Tjio G; Totman JJ; Conti M; Townsend DW
J Nucl Med; 2015 Aug; 56(8):1285-91. PubMed ID: 26135111
[TBL] [Abstract][Full Text] [Related]
7. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between
Bailly C; Gouard S; Guérard F; Chalopin B; Carlier T; Faivre-Chauvet A; Remaud-Le Saëc P; Bourgeois M; Chouin N; Rbah-Vidal L; Tripier R; Haddad F; Kraeber-Bodéré F; Bodet-Milin C; Chérel M
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137758
[TBL] [Abstract][Full Text] [Related]
8. [
Zettlitz KA; Tsai WK; Knowles SM; Salazar FB; Kobayashi N; Reiter RE; Wu AM
Mol Imaging Biol; 2020 Apr; 22(2):367-376. PubMed ID: 31209779
[TBL] [Abstract][Full Text] [Related]
9. (90)Y-PET/CT Imaging Quantification for Dosimetry in Peptide Receptor Radionuclide Therapy: Analysis and Corrections of the Impairing Factors.
Fabbri C; Bartolomei M; Mattone V; Casi M; De Lauro F; Bartolini N; Gentili G; Amadori S; Agostini M; Sarti G
Cancer Biother Radiopharm; 2015 Jun; 30(5):200-10. PubMed ID: 25860616
[TBL] [Abstract][Full Text] [Related]
10. Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.
Muylle K; Flamen P; Vugts DJ; Guiot T; Ghanem G; Meuleman N; Bourgeois P; Vanderlinden B; van Dongen GA; Everaert H; Vaes M; Bron D
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1304-14. PubMed ID: 25792453
[TBL] [Abstract][Full Text] [Related]
11. Spatial resolution and image qualities of Zr-89 on Siemens Biograph TruePoint PET/CT.
Lee YS; Kim JS; Kim JY; Kim BI; Lim SM; Kim HJ
Cancer Biother Radiopharm; 2015 Feb; 30(1):27-32. PubMed ID: 25549151
[TBL] [Abstract][Full Text] [Related]
12. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.
DeNardo GL; DeNardo SJ; O'Donnell RT; Kroger LA; Kukis DL; Meares CF; Goldstein DS; Shen S
Clin Lymphoma; 2000 Sep; 1(2):118-26. PubMed ID: 11707820
[TBL] [Abstract][Full Text] [Related]
13. Discrepancies and priorities in staging and restaging malignant lymphoma by SPET, SPET/CT, PET/CT and PET/MRI.
Chavdarova LI; Tzonevska AD; Piperkova EN
Hell J Nucl Med; 2013; 16(3):223-9. PubMed ID: 24137584
[TBL] [Abstract][Full Text] [Related]
14. ⁸⁹Zr-Labeled Versus ¹²⁴I-Labeled αHER2 Fab with Optimized Plasma Half-Life for High-Contrast Tumor Imaging In Vivo.
Mendler CT; Gehring T; Wester HJ; Schwaiger M; Skerra A
J Nucl Med; 2015 Jul; 56(7):1112-8. PubMed ID: 25999431
[TBL] [Abstract][Full Text] [Related]
15. (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy.
Tijink BM; Perk LR; Budde M; Stigter-van Walsum M; Visser GW; Kloet RW; Dinkelborg LM; Leemans CR; Neri D; van Dongen GA
Eur J Nucl Med Mol Imaging; 2009 Aug; 36(8):1235-44. PubMed ID: 19259661
[TBL] [Abstract][Full Text] [Related]
16. Radiolabeling Silica-Based Nanoparticles via Coordination Chemistry: Basic Principles, Strategies, and Applications.
Ni D; Jiang D; Ehlerding EB; Huang P; Cai W
Acc Chem Res; 2018 Mar; 51(3):778-788. PubMed ID: 29489335
[TBL] [Abstract][Full Text] [Related]
17. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091
[TBL] [Abstract][Full Text] [Related]
18. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET.
Verel I; Visser GW; Boerman OC; van Eerd JE; Finn R; Boellaard R; Vosjan MJ; Stigter-van Walsum M; Snow GB; van Dongen GA
Cancer Biother Radiopharm; 2003 Aug; 18(4):655-61. PubMed ID: 14503961
[TBL] [Abstract][Full Text] [Related]
19. Advances in Immuno-PET for the Detection of Cancer and Assessment of Response to Therapy.
Alauddin MM; Khawli LA
Curr Med Chem; 2021; 28(4):647-672. PubMed ID: 32003655
[TBL] [Abstract][Full Text] [Related]
20. Positive progress in immunoPET--not just a coincidence.
McCabe KE; Wu AM
Cancer Biother Radiopharm; 2010 Jun; 25(3):253-61. PubMed ID: 20578830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]